HIMS is trading 5.5% up today at $34.51 as upbeat sentiment grows around its cash-pay GLP-1 weight-loss business following reports of insurance coverage shifts.
- A Reuters-covered analysis indicates that employers are scaling back insurance coverage for costly GLP-1 drugs, which is expected to drive more patients toward direct-to-consumer platforms like Hims & Hers.
- The stock is showing significant relative strength, gaining ground while broader market indices trade lower, suggesting investors are re-rating the company's long-term weight-loss revenue opportunity.
- This company-specific tailwind highlights the growing demand for affordable, out-of-pocket alternatives to traditional healthcare coverage for weight-loss treatments.